Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PD-1 Sponsors Expand Into Bladder, Head & Neck Cancer

Executive Summary

Merck claims first Phase III survival data in bladder cancer for Keytruda, while Bristol shows potential for immunotherapy combinations in bladder and head and neck cancers at the annual SITC meeting.

You may also be interested in...



Bristol Shrugs Off Lirilumab Phase II Mono Trial Failure; Eyes Combo Trials

Bristol says its combination development program for lirilumab - licensed from Innate Pharma in 2011 – remains unaffected by news the anti-KIR checkpoint inhibitor failed in a Phase II trial in elderly patients with acute myeloid leukemia as a maintenance monotherapy.

Keeping Track: A Blizzard Of Submissions And A Small Flurry Of Approvals

The latest drug development news and highlights from our US FDA Performance Tracker.

Keeping Track: Mylan Submits Biosimilar Herceptin; FDA Clears Opdivo For Head And Neck Cancer

The latest drug development news and highlights from our FDA Performance Tracker.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC097673

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel